- Home
- News & Events
- Press releases
- Forbes names ICON in list of Best Employers in America for Women
Forbes names ICON in list of Best Employers in America for Women
ICON recognised as top employer for women in anonymous survey of 60,000 employees
Dublin, Ireland, 12 August 2019 – ICON plc, (NASDAQ: ICLR), a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been recognised in the Forbes 2019 List of America’s Best Employers for Women.
Forbes collaborated with market research firm Statista to identify the top companies liked most by female employees based on various workplace criteria, including diversity, pay equity, family support and parental leave. The independent, online survey compiled from responses from 60,000 Americans, including 40,000 women, working for businesses with at least 1,000 US employees.
“We’re proud to be named in the 2019 Forbes list of best employers for Women,” commented Joe Cronin, Chief Human Resources Officer, ICON. “We have a unique culture in ICON. Our employees take great pride in what we do and unite in partnership with our customers to accelerate the development of medicines and devices that can help save lives, and improve the quality of life for patients globally. We are delighted that our employees recognise ICON as an excellent place to work. We are committed to ensuring that all of our employees are able to build successful and rewarding careers at ICON.”
The recognition follows ICON being ranked in Forbes magazine’s America’s Best Employers list for 2019, as the top CRO in the US. A full list of ICON’s industry awards can be viewed at www.iconplc.com/awards.
About ICON plc
ICON plc is a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 90 locations in 37 countries and has approximately 14,000 employees.
Further information is available at www.iconplc.com.
ICON Media Contact
Mita Dhullipala
Weber Shandwick
+44 (0)7989874986
mdhullipala@webershandwick.com
ICON/ICLR-G
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.